Genedx Holdings Corp Stock Analysis

WGS Stock   97.29  11.33  13.18%   
GeneDx Holdings Corp is overvalued with Real Value of 89.78 and Target Price of 88.0. The main objective of GeneDx Holdings stock analysis is to determine its intrinsic value, which is an estimate of what GeneDx Holdings Corp is worth, separate from its market price. There are two main types of GeneDx Holdings' stock analysis: fundamental analysis and technical analysis.
The GeneDx Holdings stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. GeneDx Holdings is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. GeneDx Stock trading window is adjusted to America/New York timezone.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in GeneDx Holdings Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

GeneDx Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 1.94. GeneDx Holdings Corp had not issued any dividends in recent years. The entity had 1:33 split on the 4th of May 2023. For more information please call Katherine Stueland at 888 729 1206 or visit https://www.genedx.com.

GeneDx Holdings Quarterly Total Revenue

95.64 Million

GeneDx Holdings Corp Investment Alerts

GeneDx Holdings Corp had very high historical volatility over the last 90 days
The company reported the last year's revenue of 305.45 M. Reported Net Loss for the year was (52.29 M) with profit before taxes, overhead, and interest of 194.45 M.
GeneDx Holdings generates negative cash flow from operations
GeneDx Holdings Corp has a frail financial position based on the latest SEC disclosures
Over 88.0% of the company outstanding shares are owned by institutional investors
Latest headline from gurufocus.com: GeneDx Holdings Corp Announces Upcoming Release of Q1 2025 Financial Results

GeneDx Holdings Corp Upcoming and Recent Events

20th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

GeneDx Largest EPS Surprises

Earnings surprises can significantly impact GeneDx Holdings' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-15
2022-06-30-0.21-0.25-0.0419 
2023-03-14
2022-12-31-0.16-0.25-0.0956 
2022-03-14
2021-12-31-0.26-0.170.0934 
View All Earnings Estimates

GeneDx Holdings Environmental, Social, and Governance (ESG) Scores

GeneDx Holdings' ESG score is a quantitative measure that evaluates GeneDx Holdings' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of GeneDx Holdings' operations that may have significant financial implications and affect GeneDx Holdings' stock price as well as guide investors towards more socially responsible investments.

GeneDx Holdings Thematic Classifications

In addition to having GeneDx Holdings stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Healthcare Idea
Healthcare
USA Equities from Healthcare industry as classified by Fama & French

GeneDx Market Capitalization

The company currently falls under 'Mid-Cap' category with a total capitalization of 2.25 B.

GeneDx Profitablity

The company has Net Profit Margin of (0.17) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of 0.11 %, which entails that for every 100 dollars of revenue, it generated $0.11 of operating income.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.20)(0.21)
Return On Capital Employed(0.06)(0.07)
Return On Assets(0.12)(0.13)
Return On Equity(0.21)(0.22)

Management Efficiency

GeneDx Holdings Corp has Return on Asset of (0.032) % which means that on every $100 spent on assets, it lost $0.032. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.221) %, meaning that it generated no profit with money invested by stockholders. GeneDx Holdings' management efficiency ratios could be used to measure how well GeneDx Holdings manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2025. Return On Capital Employed is likely to drop to -0.07 in 2025. At this time, GeneDx Holdings' Net Tangible Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 12.8 M in 2025, whereas Total Current Assets are likely to drop slightly above 188.6 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 9.12  9.58 
Tangible Book Value Per Share 3.22  3.38 
Enterprise Value Over EBITDA(88.14)(83.73)
Price Book Value Ratio 8.43  8.85 
Enterprise Value Multiple(88.14)(83.73)
Price Fair Value 8.43  8.85 
Enterprise ValueB2.1 B
At GeneDx Holdings Corp, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Operating Margin
0.1098
Profit Margin
(0.17)
Beta
2.004
Return On Assets
(0.03)
Return On Equity
(0.22)

Technical Drivers

As of the 9th of April, GeneDx Holdings retains the Risk Adjusted Performance of 0.0678, downside deviation of 5.45, and Market Risk Adjusted Performance of 0.279. Concerning fundamental indicators, the technical analysis model lets you check existing technical drivers of GeneDx Holdings Corp, as well as the relationship between them. Please check out GeneDx Holdings Corp variance and potential upside to decide if GeneDx Holdings is priced fairly, providing market reflects its last-minute price of 97.29 per share. Given that GeneDx Holdings Corp has jensen alpha of 0.6667, we strongly advise you to confirm GeneDx Holdings Corp's regular market performance to make sure the company can sustain itself at a future point.

GeneDx Holdings Corp Price Movement Analysis

The output start index for this execution was fourty-eight with a total number of output elements of thirteen. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. GeneDx Holdings middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for GeneDx Holdings Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

GeneDx Holdings Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GeneDx Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on GeneDx Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GeneDx Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Kevin Feeley over three weeks ago
Acquisition by Kevin Feeley of 15261 shares of GeneDx Holdings subject to Rule 16b-3
 
Katherine Stueland over a month ago
Acquisition by Katherine Stueland of 6546 shares of GeneDx Holdings subject to Rule 16b-3
 
Kevin Feeley over a month ago
Disposition of 261 shares by Kevin Feeley of GeneDx Holdings at 103.94 subject to Rule 16b-3
 
Kevin Feeley over a month ago
Disposition of 717 shares by Kevin Feeley of GeneDx Holdings subject to Rule 16b-3
 
Katherine Stueland over three months ago
Disposition of 10005 shares by Katherine Stueland of GeneDx Holdings at 96.3877 subject to Rule 16b-3
 
Kevin Feeley over three months ago
Disposition of 263 shares by Kevin Feeley of GeneDx Holdings at 78.3912 subject to Rule 16b-3
 
Kevin Feeley over three months ago
Disposition of 718 shares by Kevin Feeley of GeneDx Holdings subject to Rule 16b-3
 
Katherine Stueland over three months ago
Disposition of tradable shares by Katherine Stueland of GeneDx Holdings at 74.3389 subject to Rule 16b-3
 
Katherine Stueland over three months ago
Acquisition by Katherine Stueland of 18750 shares of GeneDx Holdings subject to Rule 16b-3
 
Ruch Joshua over three months ago
Disposition of 130 shares by Ruch Joshua of GeneDx Holdings subject to Rule 16b-3
 
Kevin Feeley over six months ago
Disposition of 2635 shares by Kevin Feeley of GeneDx Holdings at 37.59 subject to Rule 16b-3
 
Katherine Stueland over six months ago
Disposition of 6546 shares by Katherine Stueland of GeneDx Holdings subject to Rule 16b-3

GeneDx Holdings Outstanding Bonds

GeneDx Holdings issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GeneDx Holdings Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GeneDx bonds can be classified according to their maturity, which is the date when GeneDx Holdings Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

GeneDx Holdings Predictive Daily Indicators

GeneDx Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of GeneDx Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

GeneDx Holdings Corporate Filings

F4
28th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
17th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
11th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
4th of March 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
21st of February 2025
Other Reports
ViewVerify
10K
20th of February 2025
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify
8K
18th of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
12th of February 2025
Other Reports
ViewVerify

GeneDx Holdings Forecast Models

GeneDx Holdings' time-series forecasting models are one of many GeneDx Holdings' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary GeneDx Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About GeneDx Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how GeneDx Holdings prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling GeneDx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as GeneDx Holdings. By using and applying GeneDx Stock analysis, traders can create a robust methodology for identifying GeneDx entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.17)(0.18)
Operating Profit Margin(0.08)(0.08)
Net Loss(0.17)(0.18)
Gross Profit Margin 0.64  0.67 

Current GeneDx Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. GeneDx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. GeneDx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
88.0Buy6Odds
GeneDx Holdings Corp current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most GeneDx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand GeneDx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of GeneDx Holdings Corp, talking to its executives and customers, or listening to GeneDx conference calls.
GeneDx Analyst Advice Details

GeneDx Stock Analysis Indicators

GeneDx Holdings Corp stock analysis indicators help investors evaluate how GeneDx Holdings stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading GeneDx Holdings shares will generate the highest return on investment. By understating and applying GeneDx Holdings stock analysis, traders can identify GeneDx Holdings position entry and exit signals to maximize returns.
Begin Period Cash Flow100.7 M
Long Term Debt51.9 M
Common Stock Shares Outstanding26.9 M
Total Stockholder Equity245.2 M
Tax Provision-343 K
Property Plant And Equipment Net58.5 M
Cash And Short Term Investments141.2 M
Cash85.2 M
Accounts PayableM
Net Debt-21 M
50 Day M A88.1713
Total Current Liabilities54.8 M
Other Operating Expenses325.3 M
Non Current Assets Total221.4 M
Liabilities And Stockholders Equity419.4 M
Non Currrent Assets Other4.3 M
Stock Based Compensation9.1 M

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.